The expanding syndrome of amyotrophic lateral sclerosis: A clinical and molecular odyssey

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 6, 2015, Pages 667-673

  Turner, Martin R ^a   Swash, Michael ^b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL OBSERVATION; HUMAN; MOUSE MODEL; NEUROPATHIC JOINT DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYNDROME; SYSTEMIC DISEASE; ANIMAL; CLASSIFICATION; GENETICS; MOUSE; NOMENCLATURE; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; HUMANS; MICE; MICE, TRANSGENIC; TERMINOLOGY AS TOPIC;

EID: 84929999188     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-308946     Document Type: Review

References (80)

1. Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007;61:427-34.
2. Pound P, Ebrahim S, Sandercock P, et al. Where is the evidence that animal research benefits humans? BMJ 2004;328:514-17.
3. Pound P, Bracken MB. Is animal research sufficiently evidence based to be a cornerstone of biomedical research? BMJ 2014;348:g3387.
4. Charcot J-M. Amyotrophies spinales deuteropathiques sclérose latérale amyotrophique & Sclérose latérale amyotrophique. Bureaux du Progrès Médical 1874;2(Oeuvres Complétes):234-66.
5. Turner MR, Swash M, Ebers GC. Lockhart Clarke's contribution to the description of amyotrophic lateral sclerosis. Brain 2010;133:3470-9.
6. Gowers WR. A Manual of diseases of the nervous system. London: J & A Churchill, 1886.
7. Swash M, Leader M, Brown A, et al. Focal loss of anterior horn cells in the cervical cord in motor neuron disease. Brain 1986;109(Pt 5):939-52.
8. Swash M, Ingram D. Preclinical and subclinical events in motor neuron disease. J Neurol Neurosurg Psychiatry 1988;51:165-8.
9. Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 2009;73:805-11.
10. Brownell B, Oppenheimer DR, Hughes JT. The central nervous system in motor neurone disease. J Neurol Neurosurg Psychiatry 1970;33:338-57.
11. Ince PG, Evans J, Knopp M, et al. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology 2003;60:1252-8.
12. Gordon PH, Cheng B, Salachas F, et al. Progression in ALS is not linear but is curvilinear. J Neurol 2010;257:1713-17.
13. Gowers WR. Chronic Spinal Muscular Atrophy. A Manual of Diseases of the Nervous System. 11893. p. 483.
14. Hu MT, Ellis CM, Al Chalabi A, et al. Flail arm syndrome: a distinctive variant of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1998;65:950-1.
15. Wohlfart G. Collateral regeneration from residual motor nerve fibers in amyotrophic lateral sclerosis. Neurology 1957;7:124-34.
16. Osler W. On heredity in progressive muscular atrophy as illustrated in the Farr family of Vermont. Arch Med 1880;4:316-20.
17. Erb WH. Zur Lehre von den Unfallerkrankungen des Rückenmarkes, über Poliomyelitis anterior chronica nach Trauma. Dtsch Nervenheilk 1897;11:122-42.
18. Turner MR, Abisgold J, Yeates DG, et al. Head and other physical trauma requiring hospitalisation is not a significant risk factor in the development of ALS. J Neurol Sci 2010;288:45-8.
19. Scarmeas N, Shih T, Stern Y, et al. Premorbid weight, body mass, and varsity athletics in ALS. Neurology 2002;59:773-5.
20. Huisman MH, Seelen M, de Jong SW, et al. Lifetime physical activity and the risk of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013;84:976-81.
21. Beghi E, Logroscino G, Chio A, et al. Amyotrophic lateral sclerosis, physical exercise, trauma and sports: results of a population-based pilot case-control study. Amyotroph Lateral Scler 2010;11:289-92.
22. Weisskopf MG, O'Reilly EJ, McCullough ML, et al. Prospective study of military service and mortality from ALS. Neurology 2005;64:32-7.
23. Chio A, Benzi G, Dossena M, et al. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 2005;128(Pt 3):472-6.
24. Turner MR, Wicks P, Brownstein CA, et al. Concordance between site of onset and limb dominance in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2010;82:853-4.
25. Fitzgerald KC, O'Reilly EJ, Falcone GJ, et al. Dietary omega-3 polyunsaturated fatty acid intake and risk for amyotrophic lateral sclerosis. JAMA Neurol 2014;71:1102-10.
26. Wechsler IS, Brock S, Weil A. Amyotrophic lateral sclerosis with objective and subjective (neuritic) sensory disturbances. Arch Neurol Psychiatry 1929;21:299-310.
27. Hudson AJ. Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review. Brain 1981;104:217-47.
28. Origone P, Verdiani S, Ciotti P, et al. Enlarging the clinical spectrum associated with C9orf 72 repeat expansions: findings in an Italian cohort of patients with parkinsonian syndromes and relevance for genetic counselling. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:479-80.
29. Smith MC. Nerve fibre degeneration in the brain in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1960;23:269-82.
30. Bak TH, Chandran S. What wires together dies together: verbs, actions and neurodegeneration in motor neuron disease. Cortex 2012;48:936-44.
31. Gallassi R, Montagna P, Ciardulli C, et al. Cognitive impairment in motor neuron disease. Acta Neurol Scand 1985;71:480-4.
32. Dalakas MC, Hatazawa J, Brooks RA, et al. Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. Ann Neurol 1987;22:580-6.
33. Ludolph AC, Langen KJ, Regard M, et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand 1992;85:81-9.
34. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130-3.
35. Phukan J, Elamin M, Bede P, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 2012;83:102-8.
36. Elamin M, Bede P, Byrne S, et al. Cognitive changes predict functional decline in ALS: A population-based longitudinal study. Neurology 2013;80:1590-7.
37. Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 2012;11:232-40.
38. Eisen A, Turner MR, Lemon R. Tools and talk: an evolutionary perspective on the functional deficits associated with amyotrophic lateral sclerosis. Muscle Nerve 2014;49:469-77.
39. Zhou J, Gennatas ED, Kramer JH, et al. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron 2012;73:1216-27.
40. Talbot K. Amyotrophic lateral sclerosis: cell vulnerability or system vulnerability? J Anat 2014;224:45-51.
41. Eisen A, Turner MR. Does variation in neurodegenerative disease susceptibility and phenotype reflect cerebral differences at the network level? Amyotrophic Lateral Scler Frontotemporal Degener 2013;14:487-93.
42. Turner M, Goldacre R, Goldacre M. Reduced cancer incidence in Huntington's disease: record linkage study clue to an evolutionary trade-off? Clin Genet 2013;83:588-90.
43. Raichlen DA, Alexander GE. Exercise, APOE genotype, and the evolution of the human lifespan. Trends Neurosci 2014;37:247-55.
44. Al-Chalabi A, Lewis CM. Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered 2011;71:281-8.
45. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol 2011;7:603-15.
46. Turner MR, Bowser R, Bruijn L, et al. Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotrophic Lateral Scler Frontotemporal Degener 2013;14(Suppl 1):19-32.
47. Mizielinska S, Gronke S, Niccoli T, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 2014;345:1192-4.
48. Kwon I, Xiang S, Kato M, et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 2014;345:1139-45.
49. West JP III, Gitler AD. Cell Biology. Clogging information flow in ALS. Science 2014;345:1118-19.
50. Proudfoot M, Gutowski NJ, Edbauer D, et al. Early dipeptide repeat pathology in a frontotemporal dementia kindred with C9ORF72 mutation and intellectual disability. Acta Neuropathol 2014;127:451-8.
51. Gowers WR. A lecture on abiotrophy. Lancet 1902;i:1003-7.
52. Blain CR, Brunton S, Williams VC, et al. Differential corticospinal tract degeneration in homozygous 'D90A' SOD-1 ALS and sporadic ALS. J Neurol Neurosurg Psychiatry 2011;82:843-9.
53. Elamin M, Phukan J, Bede P, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology 2011;76:1263-9.
54. Swank RL, Putnam TJ. Amyotrophic lateral sclerosis and related conditions: a clinical analysis. Arch Neurol Psychiat 1943;49:151-77.
55. Turner MR, Parton MJ, Shaw CE, et al. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry 2003;74:995-7.
56. Chio A, Calvo A, Moglia C, et al. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2011;82:740-6.
57. Turner MR, Kiernan MC. Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler 2012;13:245-50.
58. Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol 2011;10:253-63.
59. Swash M. How does ALS spread between neurones in the CNS? J Neurol Neurosurg Psychiatry 2013;84:116-17.
60. Munch C, O'Brien J, Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci USA 2011;108:3548-53.
61. Kim HJ, Kim NC, Wang YD, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 2013;495:467-73.
62. Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 2012;336:1511-13.
63. Neilson S, Robinson I, Alperovitch A. Rising amyotrophic lateral sclerosis mortality in France 1968-1990: increased life expectancy and inter-disease competition as an explanation. Journal Neurol 1994;241:448-55.
64. Eisen A, Kiernan M, Mitsumoto H, et al. Amyotrophic lateral sclerosis: a long preclinical period? J Neurol Neurosurg Psychiatry 2014;85:1232-8.
65. Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology 2012;79:1732-9.
66. Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008;131(Pt 6):1540-50.
67. Swash M. Amyotrophic lateral sclerosis: a phylogenetic disease of the corticomotoneuron? Comments on the hypothesis. Muscle Nerve 1992;15:226-8.
68. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
69. Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013;74:20-38.
70. Eisen A, Kuwabara S. The split hand syndrome in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2012;83:399-403.
71. de Carvalho M, Swash M. Fasciculation potentials and earliest changes in motor unit physiology in ALS. J Neurol Neurosurg Psychiatry 2013;84:963-8.
72. Millecamps S, Boillee S, Le Ber I, et al. Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J Med Genet 2012;49:258-63.
73. Burrell JR, Vucic S, Kiernan MC. Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011;12:283-9.
74. Turner MR, Barnwell J, Al-Chalabi A, et al. Young-onset amyotrophic lateral sclerosis: historical and other observations. Brain 2012;135(Pt 9):2883-91.
75. Baumer D, Hilton D, Paine SM, et al. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology 2010;75:611-18.
76. Eisen A, Krieger C. Epidemiological considerations. Amyotrophic lateral sclerosis: Cambridge University Press, 1998:1-4.
77. Leblond CS, Kaneb HM, Dion PA, et al. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp Neurol 2014.
78. Andersen PM, Nilsson P, Keranen ML, et al. Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain 1997;120(Pt 10):1723-37.
79. Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006;66:265-7.
80. Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012;11:323-30.